Zofenopril calcium
Names
[ CAS No. ]:
81938-43-4
[ Name ]:
Zofenopril calcium
[Synonym ]:
Calcium bis[(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)-2-pyrrolidinecarboxylate]
ZOFENOPRIL CALCIUM
Calcium bis[(2S,4S)-1-[(2S)-3-(benzoylsulfanyl)-2-methylpropanoyl]-4-(phenylsulfanyl)pyrrolidine-2-carboxylate]
L-Proline, 1-[(2S)-3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, calcium salt, (4S)- (2:1)
MFCD08704648
Zofenopril calcium salt
Biological Activity
[Description]:
[Related Catalog]:
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.34 g/cm3
[ Boiling Point ]:
646.3ºC at 760 mmHg
[ Melting Point ]:
>250ºC
[ Molecular Formula ]:
C22H22Ca0.5NO4S2
[ Molecular Weight ]:
448.58
[ Flash Point ]:
344.7ºC
[ PSA ]:
228.56000
[ LogP ]:
7.80660
[ Storage condition ]:
Refrigerator
MSDS
Safety Information
[ Symbol ]:
GHS09
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H410
[ Precautionary Statements ]:
P273-P501
[ Hazard Codes ]:
N
[ Risk Phrases ]:
50/53
[ Safety Phrases ]:
60-61
[ RIDADR ]:
UN 3077 9 / PGIII
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Cardiovasc. Ther. 27(4) , 275-88, (2009)
Zofenopril, is a highly lipophilic ACE inhibitor, characterized by long-lasting tissue penetration and sustained cardiac ACE inhibition, indicated for the treatment of hypertension and myocardial infa...
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of zofenopril and its active metabolite zofenoprilat in human plasma.J. Pharm. Biomed. Anal. 55(3) , 527-32, (2011)
A novel, sensitive and rapid liquid chromatographic-electrospray ionization mass spectrometric method was developed and validated for the determination of zofenopril and its active metabolite zofenopr...
Effects of zofenopril and ramipril on cough reflex responses in anesthetized and awake rabbits.J. Cardiovasc. Pharmacol. Ther. 15(4) , 384-92, (2010)
Cough is the most common symptom reported by patients in a primary care setting and is one of the most frequent secondary effects recorded during treatment with angiotensin-converting enzyme (ACE) inh...